Abstract
Peripheral T-cell lymphoma (PTCL) is generally characterized by poor prognosis after conventional chemotherapy compared with aggressive B-cell lymphoma. To elucidate the role of high-dose chemotherapy (HDCT) with auto-SCT, we retrospectively analyzed the outcomes of 39 patients with PTCL who received HDCT and auto-SCT between 1990 and 2005. Eleven patients were histologically typed as angioimmunoblastic, nine as anaplastic large-cell lymphoma, seven as natural killer/T-cell lymphoma and twelve as PTCL unspecified. Clinical conditions at transplantation were complete response (CR) in 27 patients and non-CR in 12 patients. Thirty-two patients received a pre-transplant conditioning regimen (MCEC) comprising ranimustine, carboplatin, etoposide and CY, and seven did other TBI-based regimens. Rapid engraftment was obtained in all cases, and transplant-related death was not seen. An estimated 5-year OS was 62.1% with a median follow-up of 78 months. The 5-year OS was significantly higher in patients transplanted during complete response than in those during other disease status (71.4% vs 27.3%, P=0.046). HDCT supported by auto-SCT may therefore be effective as consolidation in CR for PTCL treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jaffe ES . Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press: Lyon, Washington DC, 2001, 351P pp.
Jaffe ES . Pathobiology of peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program 2006, 317–322.
Kamezaki K, Kikushige Y, Numata A, Miyamoto T, Takase K, Henzan H et al. Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma. Bone Marrow Transplant 2007; 39: 523–527.
Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000; 18: 3025–3030.
Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287–1295.
Armitage JO, Greer JP, Levine AM, Weisenburger DD, Formenti SC, Bast M et al. Peripheral T-cell lymphoma. Cancer 1989; 63: 158–163.
Coiffier B, Brousse N, Peuchmaur M, Berger F, Gisselbrecht C, Bryon PA et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Ann Oncol 1990; 1: 45–50.
Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007; 18: 652–657.
Mounier N, Gisselbrecht C, Briere J, Haioun C, Feugier P, Offner F et al. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann Oncol 2004; 15: 1790–1797.
Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006; 20: 1533–1538.
Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630–1636.
A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994.
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909–3918.
Chen AI, McMillan A, Negrin RS, Horning SJ, Laport GG . Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant 2008; 14: 741–747.
Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998; 92: 76–82.
Escalon MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M D Anderson Cancer Center experience. Cancer 2005; 103: 2091–2098.
Greer JP . Therapy of peripheral T/NK neoplasms. Hematology Am Soc Hematol Educ Program 2006, 331–337.
Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.
Rodriguez J, Caballero MD, Gutierrez A, Marin J, Lahuerta JJ, Sureda A et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 2003; 14: 1768–1775.
Fanin R, Ruiz de Elvira MC, Sperotto A, Baccarani M, Goldstone A . Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1999; 23: 437–442.
Jagasia M, Morgan D, Goodman S, Hamilton K, Kinney M, Shyr Y et al. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma 2004; 45: 2261–2267.
Nademanee AP, Zain JM, Palmer J, Tsai N, Kogut NM, Krishnan A et al. The impact of disease status on the outcome of high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) for peripheral T-cell lymphoma (PTCL). ASH Annu Meeting Abstr 2006; 108: 3060.
Yang D-H, Kim WS, Kim SJ, Bae SH, Kim SH, Kim IH et al. The clinical outcomes of autologous stem cell transplantation in peripheral T cell lymphoma: from Retrospective Multicenter Study in Korea. ASH Annu Meet Abstr 2007; 110: 1892.
Rodriguez J, Caballero MD, Gutierrez A, Gandarillas M, Sierra J, Lopez-Guillermo A et al. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy.The GEL-TAMO experience. Haematologica 2003; 88: 1372–1377.
Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008; 19: 958–963.
Acknowledgements
We thank the medical and nursing staff working at the Fukuoka Blood and Marrow Transplantation Group for providing information on the patients.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Numata, A., Miyamoto, T., Ohno, Y. et al. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant 45, 311–316 (2010). https://doi.org/10.1038/bmt.2009.165
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2009.165
Keywords
This article is cited by
-
Pretreatment C-reactive protein-to-albumin ratio predicts clinical outcomes in patients with peripheral T-cell lymphoma
International Journal of Hematology (2023)
-
Management of Peripheral T-cell Lymphomas and the Role of Transplant
Current Oncology Reports (2022)
-
Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas
Annals of Hematology (2021)
-
RETRACTED ARTICLE: High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey
International Journal of Hematology (2020)
-
Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma
Current Hematologic Malignancy Reports (2020)